There is a report of a more potent cytotoxic potential of B7–H3-targeting chimeric antigen receptor (CAR) T cell therapy on CSCs (vs. bulk cancer cells), indicating the higher sensitivity of B7–H3+ CSCs to B7–H3-targeting therapy [8]. This evidence concerns the gene CD80 and cancer.